Format

Send to

Choose Destination
See comment in PubMed Commons below
Hum Pathol. 2014 Oct;45(10):2136-43. doi: 10.1016/j.humpath.2014.06.008. Epub 2014 Jun 26.

Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.

Author information

1
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10065.
2
Department of Public Health, Weill Medical College of Cornell University, New York, NY 10065.
3
Department of Pathology, University of Michigan, Ann Arbor, MI 48109; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
4
Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215; Harvard Medical School, Boston, MA 02215.
5
Institute of Pathology, University of Rostock, Rostock, Germany 18057.
6
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10065; Department of Urology, Weill Medical College of Cornell University, New York, NY 10065; Institute for Precision Medicine of Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10065.
7
Division of Urology, Beth Israel Deaconess Medical Center, Boston, MA 02215; Harvard Medical School, Boston, MA 02215.
8
Department of Medicine, Division of Hematology and Oncology, Weill Medical College of Cornell University, New York, NY 10065; Institute for Precision Medicine of Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10065.
9
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10065; Institute for Precision Medicine of Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10065.
10
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 10065; Institute for Precision Medicine of Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10065. Electronic address: jmm9018@med.cornell.edu.

Abstract

Aurora kinase A (AURKA) gene amplification has been documented in 67% of hormone-naive prostate cancer cases that progress to a highly aggressive variant of castrate-resistant disease, clinically referred to as "neuroendocrine" prostate cancer, "small cell" prostate carcinoma, or "anaplastic" prostate cancer. Therefore, AURKA amplification is a potential prognostic biomarker that may help to identify patients with prostate cancer who are at high risk for developing castrate-resistant disease with clinical features of small cell carcinoma. Furthermore, AURKA inhibitors are currently being tested in clinical trials. In a previous study, we found AURKA amplification in 6 cases of prostate cancer with Paneth cell-like cells. This morphologic pattern has been suggested to represent low-grade neuroendocrine differentiation (NED) with generally favorable prognosis. We sought to investigate the frequency of AURKA amplification and the histologic characteristics of prostate cancer with Paneth cell-like NED. Twenty-five cases from 172 prostatectomies were evaluated for the presence of 18 morphologic features and AURKA amplification. Most prostate cancers with Paneth cell-like NED had macronucleoli (92%), basophilic appearance (88%), perineural invasion (72%), and nuclear stratification (76%). The frequency of AURKA amplification was 45%, present throughout the examined tumor nodule including areas without Paneth cell-like cells. When histologically similar cases with and without AURKA amplification were compared, this gene alteration was associated with larger extent of Paneth cell-like NED identified at magnification ×20 (P = .015), higher percentage of Paneth cell-like NED throughout the tumor nodule (P = .033), ductal features (P = .02), and higher overall Gleason grade (P = .039). AURKA amplification was not associated with age, serum prostate specific antigen, or tumor stage. The high frequency of AURKA amplification (45%) in localized prostate cancer with Paneth cell-like NED and its potential prognostic significance warrant further investigation.

KEYWORDS:

AURKA amplification; MYCN amplification; Neuroendocrine differentiation; Paneth cell–like; Prostate cancer

PMID:
25128228
PMCID:
PMC4414025
DOI:
10.1016/j.humpath.2014.06.008
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center